Study of BBM-C101 injection for cervical precancerous changes
Part of Infections clinical trials.
This trial tests an injection called BBM-C101 for women with high-grade cervical precancerous lesions linked to HPV types 16 or 18. The goal is to see if it can safely help the body clear these abnormal cells and prevent them from becoming cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a cervical biopsy showing high-grade precancerous changes caused by HPV type 16 or 18.
- You must have a colposcopy exam that is considered satisfactory and a sample from inside the cervix that is negative for abnormal cells.
- If you can become pregnant, you must agree to use highly effective birth control with your partner during the study and for 1 year after the first dose, and have a negative pregnancy test within 7 days before starting.
- You must be willing to follow the study schedule and give written consent.
- You cannot have had any prior treatment for HPV or cervical precancer, and you cannot have had a therapeutic HPV vaccine (the standard preventive HPV vaccine is allowed).
- You must not have certain medical conditions, like active infections, autoimmune diseases, or a history of cancer, and your blood tests must be within safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment (NWRD08) for women with high-grade cervical changes (CIN 2/3) caused by HPV types 16 or 18. It aims to see if the treatment can help clear the abnormal cells and prevent them from becoming cancer.
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
This trial tests a new drug called NWRD09 for women with high-grade cervical cell changes (CIN 2/3) caused by HPV type 16. The goal is to see if the drug can help clear these abnormal cells without needing surgery.
This study tests an injection called BBM-C101 that may help the body clear a long-lasting HPV 16 or 18 infection and prevent precancerous changes from getting worse. It is for people who have not been helped by standard creams or who prefer not to have surgery.
This study tests an investigational injection called SYS6026 for people with high-grade cervical precancerous lesions (CIN 2 or 3) caused by HPV types 16 or 18. The goal is to see if the injection can help the body clear the HPV and reduce or eliminate the abnormal cells, possibly avoiding surgery.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
Hear when a new High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.